MOR107 is a lanthipeptide based on the proprietary technology platform of our subsidiary Lanthio Pharma B.V. and it is a selective agonist of the angiotensin II receptor type 2 (AT2-R). Lanthipeptides are a novel class of therapeutics with potential high target molecule selectivity and high in vivo stability. Lanthipeptides can be designed to combine agonistic or antagonistic activity with low toxicity risk. Especially highly selective lanthipeptide agonists are expected to open up new therapeutic applications with potential in indications that are not usually targeted with antibodies. , MOR107 is the first lanthipeptide in MorphoSys’s clinical pipeline. Based on initial anti-tumor data, MOR107 is currently in pre-clinical investigation with a focus on oncology indications.